Literature DB >> 8201215

Nicotinamide methylation in patients with cirrhosis.

R Cuomo1, M Dattilo, R Pumpo, G Capuano, L Boselli, G Budillon.   

Abstract

Methylation reactions play an important role in the transformation of endogenous and exogenous substances. Up to 85% of all transmethylation reactions occur in the liver. Several studies have shown that these metabolic processes are greatly influenced by the presence of hepatic diseases. We investigated the methylation of nicotinamide in 16 control subjects and in 29 patients with cirrhosis (19 Child A, 10 Child B). The basal serum value of N-methyl-nicotinamide was measured in all subjects. In seven controls and in nine patients with cirrhosis (5 Child A and 4 Child B), the serum levels and urinary excretion (5 and 24 h) of N-methyl-nicotinamide were also evaluated after oral administration of nicotinamide (1.5 mg/kg body weight). The basal serum levels of N-methyl-nicotinamide were significantly (p < 0.05) higher in patients with cirrhosis (Child A: median 34 ng/ml, 16th percentile 24, 84th percentile 61; Child B median 45, 16th percentile 34, 84th percentile 81) than in controls (median 22, 16th percentile 13, 85th percentile 28). After the nicotinamide load the urinary excretion and the time course of serum N-methyl-nicotinamide in cirrhosis were also higher (p < 0.05) than in controls (24 h urinary excretion = 66.2 mg +/- 5 S.D. in cirrhosis; 47.2 +/- 10.3 in controls) (area under the serum concentration versus time curve = 68 micrograms.ml-1.min-1 +/- 22 S.D. in cirrhosis; 32 +/- 15 in controls). In conclusion, our results show that cirrhosis does not impair the efficiency of nicotinamide methylation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201215     DOI: 10.1016/s0168-8278(05)80480-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma.

Authors:  Khin Than Win; Sung-Wei Lee; Hsuan-Ying Huang; Li-Ching Lin; Ching-Yih Lin; Chung-Hsi Hsing; Li-Tzong Chen; Chien-Feng Li
Journal:  Tumour Biol       Date:  2013-07-11

2.  Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis.

Authors:  Jongmin Kim; Seok Joo Hong; Eun Kyung Lim; Yun-Suk Yu; Seung Whan Kim; Ji Hyeon Roh; In-Gu Do; Jae-Won Joh; Dae Shick Kim
Journal:  J Exp Clin Cancer Res       Date:  2009-02-16

3.  A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Authors:  Naoko Takebe; Jan H Beumer; Shivaani Kummar; Brian F Kiesel; Afshin Dowlati; Geraldine O'Sullivan Coyne; Richard Piekarz; Lawrence Rubinstein; Laura K Fogli; Ulka Vaishampayan; Sanjay Goel; Cindy L O'Bryant; Bassel F El-Rayes; Vincent Chung; Heinz-Josef Lenz; Richard Kim; Chandra P Belani; Joseph M Tuscano; William Schelman; Nancy Moore; James H Doroshow; Alice P Chen
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

Review 4.  Nicotinamide N-Methyltransferase in Health and Cancer.

Authors:  David B Ramsden; Rosemary H Waring; David J Barlow; Richard B Parsons
Journal:  Int J Tryptophan Res       Date:  2017-06-30

Review 5.  Nicotinamide N-Methyltransferase: Genomic Connection to Disease.

Authors:  David B Ramsden; Rosemary H Waring; Richard B Parsons; David J Barlow; Adrian C Williams
Journal:  Int J Tryptophan Res       Date:  2020-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.